Halozyme Therapeutics Inc (HALO)
45.73
-0.03
(-0.07%)
USD |
NASDAQ |
Nov 21, 16:00
45.82
+0.09
(+0.20%)
After-Hours: 17:59
Halozyme Therapeutics Debt to Equity Ratio: 3.323 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.323 |
| June 30, 2024 | 5.191 |
| March 31, 2024 | 8.441 |
| December 31, 2023 | 17.89 |
| September 30, 2023 | 6.010 |
| June 30, 2023 | 9.905 |
| March 31, 2023 | 22.69 |
| December 31, 2022 | 8.87 |
| September 30, 2022 | 15.51 |
| June 30, 2022 | 4.251 |
| March 31, 2022 | 3.372 |
| December 31, 2021 | 4.451 |
| September 30, 2021 | 3.109 |
| June 30, 2021 | 7.305 |
| March 31, 2021 | 12.93 |
| December 31, 2020 | 2.630 |
| September 30, 2020 | 3.977 |
| June 30, 2020 | 3.695 |
| March 31, 2020 | 6.710 |
| December 31, 2019 | 4.387 |
| September 30, 2019 | 0.2602 |
| June 30, 2019 | 0.3267 |
| March 31, 2019 | 0.4053 |
| December 31, 2018 | 0.5078 |
| September 30, 2018 | 0.6109 |
| Date | Value |
|---|---|
| June 30, 2018 | 0.6513 |
| March 31, 2018 | 0.6985 |
| December 31, 2017 | 0.9711 |
| September 30, 2017 | 2.858 |
| June 30, 2017 | 3.628 |
| March 31, 2017 | -3.659 |
| December 31, 2016 | -6.669 |
| September 30, 2016 | -17.69 |
| June 30, 2016 | 20.98 |
| March 31, 2016 | 6.651 |
| December 31, 2015 | 1.159 |
| September 30, 2015 | 1.566 |
| June 30, 2015 | 0.9905 |
| March 31, 2015 | 1.324 |
| December 31, 2014 | 1.206 |
| September 30, 2014 | 1.248 |
| June 30, 2014 | 0.9008 |
| March 31, 2014 | 0.746 |
| December 31, 2013 | -2.490 |
| September 30, 2013 | -8.534 |
| June 30, 2013 | 2.667 |
| March 31, 2013 | 0.937 |
| December 31, 2012 | 0.6072 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
2.630
Minimum
Dec 2020
22.69
Maximum
Mar 2023
7.732
Average
5.601
Median
Debt to Equity Ratio Benchmarks
| Abbott Laboratories | 0.3764 |
| Novavax Inc | -0.3215 |
| Insulet Corp | 1.251 |
| BioLife Solutions Inc | 0.0616 |
| TransMedics Group Inc | 2.422 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.118B |
| Total Liabilities (Quarterly) | 1.665B |
| Shareholders Equity (Quarterly) | 452.70M |
| Current Ratio | 10.36 |
| Net Debt Paydown Yield | -0.02% |